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Abstract Here we report a patient with a new pathogenic
mutation in ACAD9. Shortly after birth she presented with
respiratory insufficiency and a high lactate level. At age
7 weeks, she was diagnosed with severe hypertrophic
cardiomyopathy and she suffered from muscle weakness
and hypotonia. Her condition deteriorated during intercur-
rent illnesses and she died at 6 months of age in cardiogenic
shock. Analysis of respiratory chain activities in muscle
and fibroblasts revealed an isolated complex I deficiency.
A genome-wide screen for homozygosity revealed several
homozygous regions. Four candidate genes were found and
sequencing revealed a homozygous missense mutation in
ACAD9. The mutation results in an Ala220Val amino acid
substitution located near the catalytic core of ACAD9. SDS
and BN-PAGE analysis showed severely decreased
ACAD9 and complex I protein levels, and lentiviral
complementation of patient fibroblasts partially rescued
the complex I deficiency. Riboflavin supplementation did
not ameliorate the complex I deficiency in patient fibro-
blasts. More than a dozen ACAD9 patients with complex I
deficiency have been identified in the last 3 years,
indicating that ACAD9 is important for complex I
assembly, and that ACAD9 mutations are a relatively
frequent cause of complex I deficiency.
Introduction
Inborn errors of metabolism (IEM) is a large group of
disorders, with a wide spectrum of symptoms, and this also
holds true for an IEM subgroup: the oxidative phosphory-
lation disorders. One in every 5,000 newborns suffers from
such a disorder (Skladal et al. 2003), and 20–25% of these
cases are isolated complex I deficiencies (Bugiani et al.
2004; Loeffen et al. 2000; Scaglia et al. 2004; Thorburn
2004). Complex I deficiency can be caused by mutations in
genes encoding the structural components of the complex,
either in mtDNA or nuclear DNA, or by mutations in genes
encoding proteins aiding the assembly of the 45 subunits of
the complex. Defects in assembly factors form a new class
of disease (Nouws et al. 2012), which are probably
responsible for 50% of the isolated complex I deficiencies.
In 2010, we identified a new complex I assembly factor,
ACAD9, and to date 14 patients in 8 families with ACAD9
mutations have been reported (Gerards et al. 2011; Haack
et al. 2010; Haack et al. 2012; Nouws et al. 2010).
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The patients were identified within a period of 3 years,
indicating that ACAD9 is a crucial protein in the assembly
process, and that mutations in this gene are a relatively
frequent cause of complex I deficiency. Most patients with
ACAD9 mutations present with exercise intolerance in
combination with hypertrophic cardiomyopathy, a
thickening of the heart muscle with various presentations,
and, when diagnosed in (pre-)adolescent children, a poor
prognosis. Hypertrophic cardiomyopathy may be a conse-
quence of mitochondrial dysfunction, caused by mutations
in proteins that are involved in fatty acid oxidation,
mitochondrial translation, or oxidative phosphorylation.
Here we report a new pathogenic mutation in ACAD9,
causing hypertrophic cardiomyopathy and early death. In
contrast to a previous report (Gerards et al. 2011) of the
beneficial effect of riboflavin in ACAD9-deficient patients,
this patient did not respond to riboflavin treatment.
Materials and Methods
Clinical Data
The patient was a girl, the first child of healthy first-cousin
parents of Turkish origin. The pregnancy was uncompli-
cated, apart from a maternal febrile urinary infection shortly
before birth. The patient was born in gestation week 41+4
by cesarean section, with no clinical signs of asphyxia.
Shortly after birth, she had respiratory insufficiency
requiring nasal CPAP therapy with high oxygen supple-
mentation, and she developed a compensated metabolic
acidosis with a plasma lactate up to 9 mmol/l. A chest
X-ray showed bilateral dense lungs and antibiotic therapy
was initiated. At the age of 23 postnatal hours, her
condition deteriorated into cardiorespiratory collapse with
severe pulseless bradycardia: she was given cardiac
massage, intubated, and mechanically ventilated. Plasma
lactate rose to a maximum of 20 mmol/l. Echocardiography
demonstrated a structurally normal heart with signs of
severe pulmonary hypertension. The liver was enlarged,
and paralytic ileus was suspected on abdominal X-ray, but
this resolved over the following week. She was extubated
after 5 days, requiring nasal CPAP for another week. At
3 weeks of age, her condition had improved and she was
discharged to a local hospital. Plasma lactate levels had
stabilized to 2.2–3.3 mmol/l.
At age 7 weeks, she presented with tachypnea, paradox-
ical respiration, muscle weakness, and hypotonia. Echocar-
diography showed severe concentric left ventricle
hypertrophy, which progressed over the next month, despite
propranolol therapy. At age 3 months, treatment with
100 mg riboflavin per day was initiated. Her condition
deteriorated during intercurrent infections, and she died at
age 6 months in cardiogenic failure.
Urine organic acids measured three times showed
excretion of lactate, citric acid cycle metabolites and a
consistent slight elevation of 3-methylglutaconic acid, in
the range of 21–65 mmol/mmol creatinine (ref < 9). Plasma
amino acids showed elevated alanine (1221 mmol/l, ref
148–475) and low citrulline (7 mmol/l, ref. 8–47).
Enzyme Measurements
Respiratory chain enzyme analysis in muscle and fibro-
blasts was performed as described before (Cooperstein and
Lazarow 1951; Janssen et al. 2007; Wibrand et al. 2010)
Values are expressed relative to the mitochondrial reference
enzyme citrate synthase (Srere 1969).
SNP Array Analysis and Homozygosity Mapping
DNA was extracted from peripheral blood according to
standard procedures and used for a genome-wide search for
homozygosity with the Affymetrix Genomewide Human
SNP Array 6.0 (Affymetrix Inc., Santa Clara, CA). In brief,
DNA was digested with the restriction enzymes StyI and
NspI, mixed with StyI and NspI adapters and ligated with
the T4 DNA ligase. The ligated DNA was PCR-amplified,
pooled, and purified. The purified PCR product was
fragmented with DNase I and end-labeled with biotin. The
samples were hybridized to an array for 18 h in a
hybridization oven. The array was washed, stained, and
scanned with an Affymetrix GeneChip scanner 3000.
Affymetrix software was used to analyze the data, and
homozygositymapper (homozygositymapper.org) was used
to identify the homozygous regions.
Mutation Analysis
PCR of genomic DNA was performed with the Promega
GoTaq PCR system and the following conditions: 0.2 mM
dNTPs, 1 x buffer, 1.5 mM MgCl2, 0.5 mM of each primer,
10 ng template and 1.5U polymerase in a total volume of
50 ml. The PCR program was: 94 C for 2 min, 35 cycles of
denaturing at 94 C for 30 s, annealing at 60 C for 30 s,
and extension at 72 C for 30 s, and a final extension step
of 72 C for 7 min.
Sequencing was performed with the ABI Big Dye
Terminator v. 1.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, USA). The sequencing reactions were vacuum-
purified with the Montage Seq96 Sequencing Reaction
Cleanup Kit (Millipore SA, SaintQuentin, France) and ana-
lyzed on an ABI 3130xl Gene Analyzer (Applied Biosystems).
The primer sequences are available upon request.
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The data were analyzed with Sequencing Analysis
Software Version 5.2 from Applied Biosystems, and
mutation screening was performed using Mutation
Surveyor v.3.1 Software (SoftGenetics). Verified variations
were evaluated through the bioinformatice tools of Alamut
(interactive Biosoftware). Primer sequences and PCR
conditions are available on request.
Blue Native, SDS-PAGE, and In-Gel Activity Assays
Eighty micrograms of solubilized mitochondrial protein
was loaded on 5–15% blue native gradient gels or on one-
dimensional 10% sodium dodecyl sulfate polyacrylamide
gels (SDS-PAGE) as described previously (Calvaruso et al.
2008; Ugalde et al. 2004). After electrophoresis, the gels
were processed for either complex I in-gel activity
(CI-IGA) analysis or immunoblotting. For blotting, proteins
were transferred to a PROTRAN nitrocellulose membrane
(Schleicher & Schuell).
Antibodies and ECL Detection
Immunodetection was performed by the use of the
following primary antibodies: CI-NDUFA9, CII-SDHA,
CV-ATPase-a, and V5 (invitrogen), CII-SDHB (Abcam),
Porin (VWR international), ACAD9 (a gift from J. Vockley,
University of Pittsburgh, USA). Secondary detection
was performed using peroxidase conjugated anti-mouse or
anti-rabbit IgGs (Invitrogen). The signal was generated
using ECL (Pierce, Rockford, USA).
Lentiviral Complementation of Patient Fibroblasts
ACAD9WT and the Cox 8 leader sequence were cloned
into pDONR201 as described before (Hoefs et al. 2008;
Nouws et al. 2010). To construct the lentiviral compatible
vector containing a C-terminally V5-tagged ACAD9WT or
Cox 8 leader sequence, the pDONR201-ACAD9WT
and pDONR201-cox8 vectors were recombined with
pLenti6.2V5-DEST Gateway Vector using the Gateway
LR Clonase II enzyme mix (Invitrogen). HEK293FT cells
were transfected to produce lentivirus with pLP1, pLP2,
pVSV/G, and one of the two expression vectors according
to the manufacturer’s protocol (Invitrogen). The virus was
harvested after 72 h and added to the human fibroblasts
overnight. The following day, the virus was removed and
the medium refreshed. After 48 h, 2.5 mg/ml blasticidin was
added to the medium to select the transduced cells. Cells
were selected for 14 days, in which time the mock-infected
cells (without virus) died. Blasticidin-resistant cells were
used for biochemical analysis within six passages after
transduction.
Riboflavin Treatment of Patient Cells
Human skin fibroblasts were cultured in medium 199
(Gibco) supplemented with 10% fetal bovine serum
(FBS v/v) (PAA), 1% penicillin/streptomycin (Gibco),
1mM sodium pyruvate (Sigma), and 1 mg/ml riboflavin
(Sigma) for one week, and the medium was refreshed every
2 days.
Modeling
The ACAD9 modeling was executed as described in
(Nouws et al. 2010). Modeling details can be found online
at http://www.cmbi.ru.nl/_hvensela/ACAD9/
Results
Enzyme Measurements and Gel Analyses
Analysis of respiratory chain enzyme activity in muscle
showed a severe isolated complex I deficiency, with a
CI/CS ratio of 0.01 (ref. 0.19–1.54). In fibroblasts, the
CI/CS ratio was decreased to 0.16 (ref 0.24–0.37). Western
blot analysis showed a severe decrease of ACAD9 protein,
suggesting that the mutation leads to instability of the
protein (Fig. 1a). To compare with other ACAD9 mutations,
we included fibroblasts from two previously identified
patients in both the SDS and the blue native analysis. Our
patient had a severe decrease of complex I in-gel activity
and of the total amount of complex I by immunoblot
analysis, compared both to controls and to the two other
ACAD9 patients (Fig. 1b).
Gene and Conservation Analyses
A genome-wide search for homozygosity revealed several
homozygous regions, altogether comprising 298.5 Mb. No
mutations were found in the structural complex I genes
NDUFA4, NDUFB4, or NDUFB9 that were located in the
homozygous regions. Sequencing of ACAD9 located in a
homozygous region on chromosome 3 showed a homozy-
gous missense mutation, c.659C>T (p.Ala220Val). The
variant was absent from the dbSNP, ESP, and the 1,000
genomes databases (Altshuler et al. 2010), and in silico
prediction by PolyPhen2, SIFT, and Mutation Taster all
pointed to a possible pathogenic effect. Both parents were
heterozygous carriers of the mutation. The affected amino
acid, Ala220, is highly conserved among organisms
expressing ACAD9 (Fig. 1c). In addition, this amino acid
is also conserved in other ACAD family members like
VLCAD (Fig. 1c) and SCAD and MCAD (not shown).
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Fig. 1 The ACAD9 p.Ala220Val substitution leads to instability of
the protein. (a, b) ACAD9 expression level and complex I expression
level in control, ACAD9 and NDUFS7 patient fibroblasts. The
p.Ala220Val mutation is described in this chapter, whereas the two
other ACAD9 patients (R518H and E63X-E413K) and the NDUFS7
patient were described previously (Nouws et al. 2010; Triepels et al.
1999). (a) SDS-PAGE immunodetections of ACAD9 and porin,
showing a decreased amount of ACAD9 in the patient. (b) BN-PAGE
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Modeling of the p.Ala220Val Mutation
The affected alanine is located in proximity of the fatty acid
and FAD (flavin adenine dinucleotide) binding sites in the
core of the protein (Fig 1d–e). The mutation changes
alanine to valine, which are both hydrophobic and small
amino acids.
Functional Complementation
To confirm that the ACAD9 p.Ala220Val amino acid
change caused the complex I deficiency in this patient,
we complemented patient fibroblasts with C-terminally
V5-tagged wild-type ACAD9. The protein was introduced
in the cells by stable lentiviral transduction, and we
could demonstrate the presence of V5-tagged ACAD9
on SDS western blot (Fig. 2a). Both complex I amount
and activity (CI-IGA) increased, indicating that the wild-
type ACAD9 indeed rescued the complex I deficiency
in the patient cells (Fig. 2b). Consistent with these results,
also spectrophotometric analysis demonstrated an increase
in CI/CS ratio from 0.17 to 0.23 after complementation
of the patient cells, whereas this did not change in
control cells.
Fig. 1 (continued) analysis of complex I in-gel activity (CI-IGA)
and western blot immunodetection of the complex I subunit
NDUFA9, showing a decreased activity and amount of fully
assembled complex I in the patient. Complex V-CV-ATPase-a
and complex II-SDHA were used as loading controls. (c)
Conservation of the altered amino acids is shown via clustalW
alignments. Asterisks (*) indicate identical amino acids, colons (:)
indicate conserved substitutions, and periods (.) indicate semi-
conserved substitutions. (d) Model of ACAD9 (PDB code 3b96)
and the p.Ala220Val mutation, showing the two ACAD9 mono-
mers (grey and yellow), the location of the FAD cofactor (blue),
and the arrow indicates the location of the mutation (red). (e) The
mutation shown in closer detail; the replacement of alanine (in
green and indicated by green arrow) by valine leads to an addition
of two methylgroups (indicated in red and by a red arrow).
Moreover, the mutation is in proximity to the fatty acid (light blue
stretch) and FAD (white balls) binding sites in the core of the
protein
◂
Fig. 2 Complementation and riboflavin treatment of patient fibro-
blasts. (a-b) Lentiviral complementation of patient fibroblasts with
negative control V5-tagged COX8 leader sequence, indicated as NC
and V5-tagged wild-type ACAD9 as ACAD9. (a) SDS-PAGE
immunodetections of V5 and ACAD9 showing the presence of
V5-tagged ACAD9. SDHB was used as a loading control. (b) BN-
PAGE analysis of complex I in-gel activity (CI-IGA) and western blot
immunodetection of the complex I subunit NDUFA9 showing an
increase in complex I in-gel activity and amount by complementation
with WT ACAD9. Complex II-SDHB was used as a loading control.
(c, d) Riboflavin treatment of control and patient fibroblasts. (c) SDS-
PAGE immunodetections of ACAD9 and SDHB in control and
ACAD9 patient fibroblasts, showing no differences in ACAD9
amounts between fibroblasts cultured without () and with (+)
riboflavin supplementation. (d) BN-PAGE analysis of complex I in-
gel activity (CI-IGA) and western blot immunodetection of complex I
subunit NDUFA9 showing no differences in complex I activity or
amount between fibroblasts cultured without () and with (+)
riboflavin supplementation. Complex II-SDHB was used as a loading
control
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Riboflavin Treatment of Fibroblasts
Since riboflavin has been reported to have a beneficial
effect in several cases of complex I deficiency caused by
ACAD9 mutations in patients and patient fibroblasts, we
decided to test riboflavin treatment in this case as well. The
patient did not show clinical improvement after riboflavin
administration. We also assayed whether riboflavin had a
beneficial effect on the patient fibroblasts, but treatment of
the p.Ala220Val patient cell line with riboflavin did not
have any effect; it did not stabilize the ACAD9 protein nor
did it increase complex I activity or amount (Fig. 2c–d).
Discussion
We report a new pathogenic mutation in the complex I
assembly factor ACAD9. The mutation results in a
p.Ala220Val substitution that affects a highly conserved
amino acid. The ACAD9 protein level was decreased,
leading to a pronounced reduction of both complex I
amount and activity, and functional complementation with
wild-type ACAD9 led to an increase in complex I activity
and amount of fully assembled complex I. The affected
amino acid is located in the proximity of the fatty acid and
FAD binding sites in the core of the protein, which may
interfere with their binding. The mutation leads to the
substitution of alanine with valine, and although both
amino acids are hydrophobic and small, valine may fit less
well in the protein structure and possibly pose a sterical
hindrance for the side chains of other amino acids.
Taken together, these results indicate that the mutation is
disease-causing.
Including this patient, 15 patients have been reported up
to date with complex I deficiency due to mutations in
ACAD9, Tables 1 and 2 show an overview of the patients,
the biochemical data, and the clinical findings. The major
clinical presentation of this patient was hypertrophic
cardiomyopathy, as reported in 10 out of 14 complex
I–deficient patients with ACAD9 mutations (Nouws et al.
2010; Haack et al. 2012; Gerards et al. 2011; Haack et al.
2012). Additional symptoms among these ten patients
included lactic acidosis, failure to thrive, hypotonia,
exercise intolerance, encephalomyopathy, cardiorespiratory
depression, mild hearing loss, and short stature. We found a
consistent slightly elevated excretion of 3-methylglutaconic
acid, which can be an unspecific marker of a respiratory
chain disorder. Excretion of 3-methylglutaconic acid was
Table 1 Biochemical data on patients with complex I deficiency due to ACAD9 mutations
Publication Amino acid substitutions Sex % Res CI % Res CI Elevated blood 
lactate 
level
Elevated 
CSF 
lactate 
level
Elevated 
alanine 
level
activity in 
fibroblasts
activity in 
muscle
Nouws et al 2010 Arg518His (I-1) F 53% + + +
Glu63X and Glu413Lys (II-1) F 58% 61% +
Haack et al 2010 Phe44Ile and Arg266Gln (I:A) F 32% 14% +
Phe44Ile and Arg266Gln (I:B) M 38% +
Arg266Gln and Arg417Cys (II) F 13% +
Ala326Pro and Arg532Trp (III) F 26% + +
Gerards et al 2011, 
Scholte et al 1995 Arg532Trp (VII-6) F 38% + -
Arg532Trp (VII-8) M 40% + -
Arg532Trp (VII-11) F 50% + -
Arg127Gln and Arg469Trp (CV) F 9% + -
Haack et al 2012 Arg532Trp (59029) 3% +
Arg532Trp (59033) +
Arg532Trp (59036) +
This paper Ala220Val F 67% ≤11% + +
Residual CI activity in fibroblasts ¼ complex I activity normalized for citrate synthase, percentage of lowest control value (values in bold are
normalized to COX activity); grey box ¼ percentage of control mean. Residual CI activity in muscle ¼ complex I activity normalized for citrate
synthase activity for percentage of lowest control value; grey box ¼ percentage of control mean. + symptom present, – symptom absent, Empty
box if information is not available
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not reported in any of the other ACAD9 patients. The
variability in the severity of the disorder was wide, with one
patient dying at age 46 days, and one patient being alive at
age 18 years (Nouws et al. 2010). The four remaining
ACAD9 patients presented with a primarily muscular
phenotype with fatiguability, exercise intolerance, and lactic
acidosis in childhood, whereas cardiac function was normal
(Gerards et al. 2011). Moreover, these patients had a
relatively late onset of their symptoms. Three of the
patients with the muscular phenotype were homozygous
for a p.Arg532Trp mutation, which was also found
homozygous in three patients with the cardiomyopathic
phenotype (Gerards et al. 2011; Haack et al. 2010). Since
the mutation is found in both groups, there does not seem to
be an apparent genotype-phenotype correlation; a possible
explanation for the clinical differences could be modifying
variants in other genes.
In addition to the aforementioned patients, He and
coworkers described two other patients with deficiency of
ACAD9 who had a liver phenotype and one patient
displaying cardiomyopathy. However, these patients did
not have isolated complex I deficiency, and no pathogenic
mutations were identified, hence the exact contribution of
the ACAD9 mutations to the phenotype of these patients is
unclear (He et al. 2007).
Riboflavin treatment has been reported to alleviate
symptoms in a few patients with the muscular phenotype
(Scholte et al. 1995). The patients reported increased
endurance power and disappearance of exercise-related
nausea and pain after riboflavin therapy was started.
Moreover, one of the patients had had one stroke-like
episode at age 13 years, and had no more episodes on
riboflavin therapy. After 1–2 years of riboflavin therapy,
the patients’ resting lactate decreased and exercise tolerance
assessed by ergometry increased.
In vitro treatment of two ACAD9-deficient fibroblast
cell lines, which were compound heterozygous for the
Phe44Ile and Arg266Gln substitutions resulted in 2.1- and
1.7-fold increases in complex I activity, respectively (Haack
et al. 2010). We did not find any increase in ACAD9
protein level or complex I activity on riboflavin treatment
of fibroblasts of our patient, in accordance with the lack of
a clinical response to treatment with 100 mg riboflavin per
day. None of the other patients with the cardiomyopathic
phenotype were reported to receive riboflavin treatment.
Riboflavin is a precursor of flavin mononucleotide
(FMN) and FAD, which are cofactors in complex I. The
mode of action for riboflavin remains elusive, but it has
been suggested to increase mitochondrial FAD concentra-
tion, which may support FAD binding. This binding could
be necessary for the catalytic activity of ACAD9, however,
also its folding or stability may improve (Henriques et al.
2010). Riboflavin might also function as an electron
acceptor, since fibroblasts from patients with deficiency of
NDUFS2, a subunit without FAD or FMN binding sites,
responded to riboflavin treatment (Bar-Meir et al. 2001).
An explanation for the lack of response to riboflavin
treatment in our patient could be the specific location of
the mutation, although both Ala220Val and Arg532Trp,
found in patients who apparently responded to riboflavin
treatment, are located near the FAD binding site. The scarce
and contrasting results of riboflavin administration suggest
that further studies, both in vivo and in vitro, are needed on
riboflavin treatment in patients with complex I deficiency due
to ACAD9 mutations to establish the effect of the treatment.
Take-Home Message
ACAD9 mutations are a major cause of complex I
deficiency and ACAD9 patients do not always respond to
riboflavin treatment.
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